Clinical evaluation including full history taking and dermatological examination will be done for all patients. Assessment of disease severity will be performed using Global acne severity grading for acne vulgaris Skin biopsies will be taken from lesional and non-lesional skin .immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3.

Clinical evaluation including full history taking and dermatological examination will be done . Assessment of disease severity will be performed using VASI score Skin biopsies will be taken from lesional and non-lesional skin .immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3..

Skin biopsies will be taken from skin of controls.
. Five micron thick sections will be cut from paraffin blocks for immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3.

Vitiligo and Acne Vulgaris

Clinical evaluation including full history taking and dermatological examination will be done for all patients. Assessment of disease severity will be performed using VASI score for vitiligo and Global acne severity grading for acne vulgaris Skin biopsies will be taken from lesional and non-lesional skin of patients as well as controls. immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3.
Additionally, biopsies will be preserved in RNA later solution at -20°C. RNA isolation and real-time qPCR analysis will be performed for measurement of cutaneous JAK1, JAK2 and JAK3 gene expression.

skin biopsy

Cutaneous JAK in Vitiligo and Acne Vulgaris.

Cutaneous JAK Expression in Vitiligo and Acne Vulgaris.

Skin biopsies will be taken from lesional and non-lesional skin of patients as well as from healthy volunteers as controls.
All biopsies will be derived from untreated skin lesions for a minimum of 15 days before the biopsy The biopsies will be fixed and paraffin embedded. Five micron thick sections will be cut from paraffin blocks for immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3.
Additionally, biopsies will be preserved in RNA later solution at -20°C. RNA isolation and real-time qPCR analysis will be performed for measurement of cutaneous JAK1, JAK2 and JAK3 gene expression.

Yasmin Mostafa Tawfik

lecturer

Assiut University

EGF cream was applied. Half of face was treated with emollient containing EGF.

Placebo cream without EGF was applied. The other half of face was treated with only emollient which was not containing EGF.

Drug-Related Side Effects and Adverse Reactions

Epidermal Growth Factor

A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 4 weeks.
EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)

Repair Control EGF®

A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 4 weeks.
Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF

Cream without rhEGF

St. Vincent's Hospital

Therapeutic Effect of EGF Cream for Cutaneous Adverse Event of EGFR Inhibitors

The Therapeutic Effect of Topical EGF Cream for Dermatologic Adverse Events Related to EGFR Inhibitors

To evaluate the severity of acneiform eruption, the investigators take a photograph of full face. The number of inflammatory and noninflammatory lesions will be counted and accessed the severity based on the Korean Acne Grading System(KAGS).

Skin hydration is measured with Corneometer® (CM820/825; C-K Electronics, Cologne, Germany).
It shows the skin moisturizing condition in arbitrary units(AU) and the unit is from 0 to 220.

Sebum production is measured with Sebumeter® (SM815; C-K Electronics, Cologne, Germany).
It measured at forehead, cheek and chin, presented as ㎍/㎠.

Investigator's global assessment (IGA) Score : It will be assessed as a 5-point scale (-1 = worsen, to 3 = marked improvement).

Patient's global assessment (PGA) score will be assessed as a 5-point scale (-1 = worsen, to 3 =marked improvement).

Jung Min Bae

Clinical Assistant Professor

The Catholic University of Korea

EGF cream was applied. One half side of face and one hand were treated with emollient containing EGF.

Placebo cream without EGF was applied. The other half side of face and the other hand were treated with only emollient which was not containing EGF.

A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 8 weeks. Also, to evaluate the preventive effect of paronychia, patients applied same cream on the finger tips of one side hand, twice a day for 8 weeks.
EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)

A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 8 weeks. Patients applied same cream on the finger tips of the other side hand, twice a day for 8 weeks.
Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF

Preventive Effect of EGF Cream for Cutaneous Adverse Event of EGFR Inhibitors

The Preventive Effect of Topical EGF Cream for Dermatologic Adverse Events Related to EGFR Inhibitors

To evaluate the development and severity of acneiform eruption, the investigators take a photograph of full face and hands on every visit.
If the acneiform eruption develop, the severity will be assessed based on the Korean Acne Grading System(KAGS).

The paronychia lesion will be assessed by CTCAE.

It measured with Corneometer® (CM820/825, C-K Electronics, Cologne, Germany). It shows in arbitrary units(AU) and the unit is from 0 to 220.

It measured with Sebumeter® (SM815; C-K Electronics, Cologne, Germany). It is measured at forehead, cheek and chin, presented as /㎍ ㎠. It shows in arbitrary units(AU) and the unit is from 0 to 220.

Investigator's global assessment (IGA) Score will be assessed with 5-point scale (-1 = worsen to 3 =marked improvement).

Patient's global assessment (PGA) score will be assessed with a 5-point scale (-1 = worsen, to 3 = marked improvement).

It will be assessed by patient-report.
- Any event developed during the trials can be reported.

EVOZAC should be sprayed to the skin of the total face three times per day.

Physiological saline should be sprayed to the total face three times per day.

Non-small Cell Lung Cancer

EVOZAC Calming Skin Spray should be sprayed to the skin in the total face, three times per day

EVOZAC Calming Skin Spray

Physiological saline was used as the placebo of EVOZAC® Calming Skin Spray and should be also sprayed on the total face, three times per day

Physiological saline

Department of Medical Oncology,Cancer Center of Sun Yat-Sen University

Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in NSCLC

A Randomized, Double-blind, Prospective Trial of Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in Non-small Cell Lung Cancer

Li Zhang

professor

Sun Yat-sen University

Part A = ZD6474 Alone, Starting dose 50 mg/m^2 by mouth daily for 28 days; Part B, C = ZD6474 + Retinoic Acid 80 mg/m^2 by mouth twice daily for 2 consecutive weeks out of every four weeks (28 days).

Neuroblastoma

Part A = Starting dose 50 mg/m^2 by mouth daily for 28 days; Part B, C = Starting dose 50 mg/m^2 by mouth daily on days 2-28.

ZD6474

Part B, C = 80 mg/m^2 by mouth twice daily for 2 consecutive weeks out of every four weeks (28 days).

Retinoic Acid

U.T.M.D. Anderson Cancer Center

ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma

A Phase I Study of ZD6474 (Zactima) Alone and in Combination With Retinoic Acid in Relapsed and Refractory Pediatric Neuroblastoma

MTD is highest dose level in which 6 participants have been treated with at most 2 experiencing dose limiting toxicity (DLT).

acne vulgaris/tyrosine

Cutaneous JAK in Vitiligo and Acne Vulgaris.

Therapeutic Effect of EGF Cream for Cutaneous Adverse Event of EGFR Inhibitors

Preventive Effect of EGF Cream for Cutaneous Adverse Event of EGFR Inhibitors

Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in NSCLC

ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma

Najbolj popolna baza zdravilnih zelišč, podprta z znanostjo